Interim analysis of the Daliah trial - a randomized controlled phase iii clinical trial Comparing recombinant interferon alpha-2 vs. Hydroxyurea in MPN patients.

Trine Alma Knudsen; Dennis Lund Hansen; Lukas Frans Ocias; Ole Weiss Bjerrum; Mette Brabrand; Daniel El Fassi; Mikael Frederiksen; Lasse Kjær; Thomas Kielsgaard Kristensen; Torben A Kruse; Hans Torben Mourits-Andersen; Peter Møller; Ulrik Malthe  Overgaard; Marianne Tang Severinsen; Vibe Henriette  Skov; Jesper Stentoft; Jørn Starklint; Karin de Stricker; Mads Thomassen; Thomas Stauffer Larsen; Hans Carl  Hasselbalch

doi:10.1097/HS9.0000000000000060

Interim analysis of the Daliah trial - a randomized controlled phase iii clinical trial Comparing recombinant interferon alpha-2 vs. Hydroxyurea in MPN patients.

Trine Alma Knudsen, Dennis Lund Hansen, Lukas Frans Ocias, Ole Weiss Bjerrum, Mette Brabrand, Daniel El Fassi, Mikael Frederiksen, Lasse Kjær, Thomas Kielsgaard Kristensen, Torben A Kruse, Hans Torben Mourits-Andersen, Peter Møller, Ulrik Malthe Overgaard, Marianne Tang Severinsen, Vibe Henriette Skov, Jesper Stentoft, Jørn Starklint, Karin de Stricker, Mads Thomassen, Thomas Stauffer LarsenHans Carl Hasselbalch

Publikation: Bidrag til tidsskrift › Konferenceabstrakt i tidsskrift › Forskning › peer review

98 Downloads (Pure)

Originalsprog	Engelsk
Artikelnummer	S131
Tidsskrift	HemaSphere
Vol/bind	2
Udgave nummer	S1
Sider (fra-til)	18-19
DOI	https://doi.org/10.1097/HS9.0000000000000060
Status	Udgivet - 15. jun. 2018
Begivenhed	European Hematology Association 23rd congress EHA 2018 - Stockholm , Sverige Varighed: 14. jun. 2018 → 17. jun. 2018

Konference

Konference	European Hematology Association 23rd congress EHA 2018
Land/Område	Sverige
By	Stockholm
Periode	14/06/2018 → 17/06/2018

Dokumenter og links

10.1097/HS9.0000000000000060Licens: CC BY-NC-ND

Interim analysis of the Daliah trial Forlagets udgivne version, 408 MBLicens: CC BY-NC-ND

Citationsformater

Knudsen, T. A., Lund Hansen, D., Ocias, L. F., Weiss Bjerrum, O., Brabrand, M., El Fassi, D., Frederiksen, M., Kjær, L., Kielsgaard Kristensen, T., Kruse, T. A., Mourits-Andersen, H. T., Møller, P., Overgaard, U. M., Severinsen, M. T., Skov, V. H., Stentoft, J., Starklint, J., de Stricker, K., Thomassen, M., ... Hasselbalch, H. C. (2018). Interim analysis of the Daliah trial - a randomized controlled phase iii clinical trial Comparing recombinant interferon alpha-2 vs. Hydroxyurea in MPN patients. HemaSphere, 2(S1), 18-19. [S131]. https://doi.org/10.1097/HS9.0000000000000060

@article{992c4ff7241d42d5bf3601e5ad9ef7cd,

title = "Interim analysis of the Daliah trial - a randomized controlled phase iii clinical trial Comparing recombinant interferon alpha-2 vs. Hydroxyurea in MPN patients.",

author = "Knudsen, {Trine Alma} and {Lund Hansen}, Dennis and Ocias, {Lukas Frans} and {Weiss Bjerrum}, Ole and Mette Brabrand and {El Fassi}, Daniel and Mikael Frederiksen and Lasse Kj{\ae}r and {Kielsgaard Kristensen}, Thomas and Kruse, {Torben A} and Mourits-Andersen, {Hans Torben} and Peter M{\o}ller and Overgaard, {Ulrik Malthe} and Severinsen, {Marianne Tang} and Skov, {Vibe Henriette} and Jesper Stentoft and J{\o}rn Starklint and {de Stricker}, Karin and Mads Thomassen and Larsen, {Thomas Stauffer} and Hasselbalch, {Hans Carl}",

year = "2018",

month = jun,

day = "15",

doi = "10.1097/HS9.0000000000000060",

language = "English",

volume = "2",

pages = "18--19",

journal = "HemaSphere",

issn = "2572-9241",

publisher = "Wolters Kluwer Health",

number = "S1",

note = "European Hematology Association 23rd congress EHA 2018 ; Conference date: 14-06-2018 Through 17-06-2018",

}

Knudsen, TA, Lund Hansen, D, Ocias, LF, Weiss Bjerrum, O, Brabrand, M, El Fassi, D, Frederiksen, M, Kjær, L, Kielsgaard Kristensen, T, Kruse, TA, Mourits-Andersen, HT, Møller, P, Overgaard, UM, Severinsen, MT, Skov, VH, Stentoft, J, Starklint, J, de Stricker, K, Thomassen, M , Larsen, TS & Hasselbalch, HC 2018, 'Interim analysis of the Daliah trial - a randomized controlled phase iii clinical trial Comparing recombinant interferon alpha-2 vs. Hydroxyurea in MPN patients.', HemaSphere, bind 2, nr. S1, S131, s. 18-19. https://doi.org/10.1097/HS9.0000000000000060

Interim analysis of the Daliah trial - a randomized controlled phase iii clinical trial Comparing recombinant interferon alpha-2 vs. Hydroxyurea in MPN patients. / Knudsen, Trine Alma; Lund Hansen, Dennis; Ocias, Lukas Frans et al.

I: HemaSphere, Bind 2, Nr. S1, S131, 15.06.2018, s. 18-19.

Publikation: Bidrag til tidsskrift › Konferenceabstrakt i tidsskrift › Forskning › peer review

TY - ABST

T1 - Interim analysis of the Daliah trial - a randomized controlled phase iii clinical trial Comparing recombinant interferon alpha-2 vs. Hydroxyurea in MPN patients.

AU - Knudsen, Trine Alma

AU - Lund Hansen, Dennis

AU - Ocias, Lukas Frans

AU - Weiss Bjerrum, Ole

AU - Brabrand, Mette

AU - El Fassi, Daniel

AU - Frederiksen, Mikael

AU - Kjær, Lasse

AU - Kielsgaard Kristensen, Thomas

AU - Kruse, Torben A

AU - Mourits-Andersen, Hans Torben

AU - Møller, Peter

AU - Overgaard, Ulrik Malthe

AU - Severinsen, Marianne Tang

AU - Skov, Vibe Henriette

AU - Stentoft, Jesper

AU - Starklint, Jørn

AU - de Stricker, Karin

AU - Thomassen, Mads

AU - Larsen, Thomas Stauffer

AU - Hasselbalch, Hans Carl

PY - 2018/6/15

Y1 - 2018/6/15

U2 - 10.1097/HS9.0000000000000060

DO - 10.1097/HS9.0000000000000060

M3 - Conference abstract in journal

SN - 2572-9241

VL - 2

SP - 18

EP - 19

JO - HemaSphere

JF - HemaSphere

IS - S1

M1 - S131

T2 - European Hematology Association 23rd congress EHA 2018

Y2 - 14 June 2018 through 17 June 2018

ER -